RECRUITING

Bimatoprost as a Treatment for Graves' Orbitopathy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease

Official Title

The Role of Bimatoprost in Graves' Periorbitopathy

Quick Facts

Study Start:2017-11-01
Study Completion:2030-07-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03708627

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Emily Li, MD
CONTACT
410-955-1112
eli20@jhmi.edu

Principal Investigator

Emily Li, MD
PRINCIPAL_INVESTIGATOR
Johns Hopkins University

Study Locations (Sites)

University of Washington
Seattle, Washington, 98104
United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

  • Emily Li, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-11-01
Study Completion Date2030-07-01

Study Record Updates

Study Start Date2017-11-01
Study Completion Date2030-07-01

Terms related to this study

Additional Relevant MeSH Terms

  • Graves Ophthalmopathy